José Federico
Díaz González
Catedrático de Universidad
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (9)
2021
-
Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs
Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169
2019
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
2018
-
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER
Arthritis Research and Therapy, Vol. 20, Núm. 1
2017
-
Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, singleblind, placebo-controlled phase Ib/IIa clinical trial
Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 196-202
-
Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3
2015
-
Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares
Reumatologia Clinica, Vol. 11, Núm. 5, pp. 269-278
-
Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]
Seminars in Arthritis and Rheumatism
2011
-
Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis
Annals of the Rheumatic Diseases
-
No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis
Clinical and Experimental Rheumatology